Pharmaceutical

MABS-139 by Manhattan Biosolutions for Solid Tumor: Likelihood of Approval

MABS-139 is under clinical development by Manhattan Biosolutions and currently in Phase I for Solid Tumor.

Dec 20, 2023 - 18:00
MABS-139 is under clinical development by Manhattan Biosolutions and currently in Phase I for Solid Tumor.
Read the original article

Tags:

Previous Article

ND-10 ER by Theialife Sciences for Myopia: Likelihood of Approval

Next Article

FDA receives first-ever MDMA drug application

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA grants breakthrough therapy designation to Neuraptive’s NTX-001

FDA grants breakthrough therapy designation to Neurapti...

Sep 12, 2024

ESMO 2024: TIGIT race tightens with first look at GSK/iTeos’s TIGIT in NSCLC

ESMO 2024: TIGIT race tightens with first look at GSK/i...

Sep 16, 2024

STAT+: Pharmalittle: Exec nominated to Biogen board is mother of outgoing director’s child; telehealth company pauses Wegovy ads amid shortages

STAT+: Pharmalittle: Exec nominated to Biogen board is ...

Jun 14, 2023